AdventHealth has adopted Paragonix Technologies’ SherpaPak Cardiac Transport System (CTS) for the static hypothermic preservation of donor hearts for transplantation.
Paragonix SherpaPak CTS, the only commercially available FDA-cleared and CE-marked medical device, has been designed to safeguard hearts during the journey from donor to recipient patient.
The technology will enable the transport and preservation of a donor’s heart from around 1,000 miles away from AdventHealth’s transplant centre in Orlando, Florida, US.
AdventHealth Transplant Institute Thoracic Surgery director Dr Scott Silvestry said: “As a successful high volume advanced heart failure and heart transplant centre in Florida, our heart procurement teams are working around the clock to ensure our recipients on the waitlist receive a donor’s heart.
“We are thrilled about the addition of Paragonix SherpaPak Cardiac Transport System as a tool to provide best-in-class care of our transplant patients. Optimal preservation and quality management of the donor’s heart during transport from donor to recipient is paramount.”
The CTS enables physical and thermal protection of organs by using cold preservation techniques in a new suspension system.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Paragonix Technologies chairman and CEO Bill Edelman said: “Patients on the waitlist for a donor heart face so many medical uncertainties. The preservation of the donor’s heart they are waiting for should not be one of them.
“We are thrilled to contribute a key tool to the transplant teams in giving their transplant recipients every possible advantage on their journey of receiving a donor’s heart.”
Currently, Paragonix SherpaPak CTS is being evaluated by more than 20 major heart transplant centres in the US, adopted by 15 European transplant centres.